Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AV 001-Vasomune Therapeutics (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Vasomune Therapeutics

    • Most Recent Events

    • 03 Dec 2024 According to a Vasomune Therapeutics media release, AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) to escalate to the high-dose cohort in their AV001-004 Phase 2a Study.
    • 28 May 2024 According to a Vasomune Therapeutics media release, the United States Department of Defense Congressionally Directed Medical Research Programs award PR203503 for support to research AV-001 in Phase 2a.
    • 14 Nov 2023 According to a Vasomune Therapeutics media release, the company has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) to continue this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top